Brooks Laboratories Ltd approved the sale of 51,220 equity shares in Brooks Steriscience Limited to Steriscience Specialties Private Limited for a cash consideration of ₹20,760 per share, aggregating to approximately ₹106.33 crore. The transaction, approved by the Board on June 19, 2026, represents a partial monetization of the company's investment and is subject to completion of customary documentation and applicable regulatory requirements. Following the sale, Brooks Laboratories will retain a 32.67% stake in Brooks Steriscience, holding 1,02,440 equity shares, down from a previous holding of 49.00%.

The disposal of 16.33% of the share capital does not constitute a complete divestment, allowing the company to maintain a significant interest in the entity. The deal is not classified as a related party transaction, and the promoter or promoter group has no interest in the entity being disposed of. The transaction details were disclosed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Proceeds from the sale will be deployed towards the company's growth strategy. The capital will be utilized for the expansion of operations, capacity enhancement, funding of business opportunities, and general corporate purposes. The transaction is expected to be completed in accordance with applicable laws and regulations.

Transaction Details

Brooks Laboratories Limited reported a 90.2% rise in standalone net profit to ₹580.50 lakh for the financial year ended March 31, 2026. The company's revenue from operations for the year increased to ₹8,690.89 lakh from ₹8,343.99 lakh in the previous year. The consolidated financial results also showed a strong turnaround, with a net profit of ₹2,458.35 lakh compared to a loss of ₹996.70 lakh in FY25.

The Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026, were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 29, 2026. The results were submitted to the exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The Statutory Auditors, DMKH & Co., expressed an unmodified opinion on the financial results.

For the quarter ended March 31, 2026, the standalone net profit stood at ₹61.43 lakh, while revenue from operations was ₹2,064.78 lakh. On a consolidated basis, the net profit for the quarter was ₹152.30 lakh, with revenue from operations matching the standalone figure at ₹2,064.78 lakh. The company reported earnings per share (EPS) of ₹1.97 on a standalone basis for the full year.

Financial Performance Summary

The following table outlines the key financial metrics for Brooks Laboratories Limited for the quarter and year ended March 31, 2026:

The complete financial results are available on the company's website and the websites of BSE Limited and National Stock Exchange of India Ltd.